OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

September 11th 2020

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis

September 11th 2020

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis.

Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCC

September 10th 2020

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.

Dr. Lenz on Optimal Sequencing Strategies in CRC

September 10th 2020

Heinz-Josef Lenz, MD, FACP, discusses optimal sequencing strategies for the treatment of patients with colorectal cancer.

Dr. Wong on Recent Developments in AL Amyloidosis

September 10th 2020

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

Dr. Woyach on the Role of Acalabrutinib in CLL

September 10th 2020

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Dr. Chiang on the Management of Immune-Related AEs in Lung Cancer

September 10th 2020

Anne Chiang, MD, PhD, discusses the management of immune-related adverse effects in lung cancer.

Dr. Visco on the Utility of Cytarabine in MCL

September 10th 2020

Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.

Dr. Mascarenhas on the Potential Role of Pacritinib in MPNs

September 10th 2020

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

Dr. Ghosh on Unanswered Questions With BTK Inhibitors in CLL/SLL

September 10th 2020

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Vaishampayan on the Potential of Tivozanib in Advanced RCC

September 9th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

September 9th 2020

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Dr. Woyach on Remaining Sequencing Questions in CLL

September 9th 2020

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.

Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian Cancer

September 9th 2020

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Dr. Choudhury on Antiandrogen Treatment Selection in Nonmetastatic CRPC

September 9th 2020

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Visco on the Rationale for the MANTLE-FIRST Trial in R/R MCL

September 9th 2020

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.

Dr. Costa on Remaining Challenges With CAR T-Cell Therapy in Multiple Myeloma

September 9th 2020

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Dr. Burris on Recent Advances in TNBC

September 8th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses recent advancements made in the field of triple-negative breast cancer.